Advertisement

Advertisement
Hematologic Malignancies
COVID-19

Patients With Hematologic Malignancies: How Robust Is Their Immunity to SARS–CoV-2?

A large study from the United Kingdom has taken a deep dive into SARS–CoV-2 in the setting of cancer, yielding both concerning and encouraging...

 

 

 

 

 

Lung Cancer
Issues in Oncology

Survey Shows Disparities in Biomarker Testing Among Underserved Patients With Lung Cancer

Recent advances in cancer genomics and targeted therapies have changed the treatment landscape for lung cancer, but disparities...

 

 

 

 

Sarcoma

Activity of Nab-sirolimus in Malignant Perivascular Epithelioid Cell Tumors

In the phase II AMPECT trial reported in the Journal of Clinical Oncology, Wagner et al found that the mTOR inhibitor nab-sirolimus...

 


Advertisement
Breast Cancer

Development of a Breast Cancer Risk Prediction Model for Black Women in the United States

As reported in the Journal of Clinical OncologyJulie R. Palmer, ScD, and colleagues have developed and validated a risk prediction...

 

 

 

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement



Sponsored Content


Prostate Cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Abiraterone Acetate, Prednisone, and Radiotherapy in Metastatic Disease

Breast Cancer

Adjuvant Platinum vs Capecitabine in Patients With Basal Subtype Triple-Negative Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy

As reported in the Journal of Clinical Oncology and during the 2021 ASCO Annual Meeting by Ingrid A. Mayer, MD, and colleagues, the phase III ECOG-ACRIN EA1131 trial investigated the use of adjuvant platinum vs capecitabine in patients with basal subtype triple-negative breast cancer and residual...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Immunotherapy
Pancreatic Cancer

Katelyn T. Byrne, PhD, on the Clinical Impact of T-Cell Inflammation in the Tumor Microenvironment

Breast Cancer
Immunotherapy

ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer

The first overall survival analysis of the WSG-ADAPT HR-/HER2+ study, which evaluated neoadjuvant therapy in patients with hormone receptor (HR)-negative, HER2-positive breast cancer, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or the chemotherapy-free regimen of...

Breast Cancer
Immunotherapy

ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer

The first overall survival analysis of the WSG-ADAPT HR-/HER2+ study, which evaluated neoadjuvant therapy in patients with hormone receptor (HR)-negative, HER2-positive breast cancer, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or the chemotherapy-free regimen of...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Platinum-Based Chemotherapy vs Capecitabine

Myelodysplastic Syndromes

Reduced-Intensity Conditioning Allogeneic HCT Based on Donor Availability in Older Patients With Advanced Myelodysplastic Syndrome

In a study reported in the Journal of Clinical Oncology, Nakamura et al found that use of reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) in older patients with advanced myelodysplastic syndrome (MDS) with an available matched donor improved overall survival vs...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...